Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhibao Technology (ZBAO) Cash & Equivalents (2023 - 2025)

Zhibao Technology (ZBAO) has disclosed Cash & Equivalents for 3 consecutive years, with $1.4 million as the latest value for Q2 2025.

  • Quarterly Cash & Equivalents rose 328.6% to $1.4 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Jun 2025, up 328.6% year-over-year, with the annual reading at $1.4 million for FY2025, 334.43% up from the prior year.
  • Cash & Equivalents hit $1.4 million in Q2 2025 for Zhibao Technology, up from $331734.1 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.4 million in Q2 2025 to a low of $331734.1 in Q2 2024.
  • Historically, Cash & Equivalents has averaged $1.1 million across 3 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: crashed 76.47% in 2024 and later skyrocketed 328.6% in 2025.
  • Year by year, Cash & Equivalents stood at $1.4 million in 2023, then plummeted by 76.47% to $331734.1 in 2024, then surged by 328.6% to $1.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for ZBAO at $1.4 million in Q2 2025, $331734.1 in Q2 2024, and $1.4 million in Q2 2023.